AstraZeneca AZN.L · GBp

Its shares trade on LSE under the ticker AZN.L. It has been listed since 21 September 2007. It is a member of the FTSE 100. In the fiscal year to 31 December 2025, it reported revenue of $58.74bn and net income of $10.22bn. At that date it held total assets of $114.07bn and shareholders' equity of $48.67bn.

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Cambridge, Cambridgeshire. The company went IPO on 2007-09-21. The company focuses on discovery and development of products, which are then manufactured, marketed and sold. The company focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The company has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. The company has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. The company has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Pascal SoriotChief Executive Officer, Executive Director, since 2012£14.7m
• Mr. Michel DemareNon-Executive Independent Chairman of the Board£800,000
• Mr. Marc DunoyerChief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca, since 2013£5.7m
• Mr. Jeffrey PottChief Human Resources Officer, Chief Compliance Officer, General Counsel
• Ms. Aradhana SarinChief Financial Officer, Executive Director, since 2021£6.8m
• Ms. Sharon BarrExecutive Vice President - BioPharmaceuticals R&D
• Ms. Pam ChengExecutive Vice President - Global Operations, Information Technology and Chief Sustainability Officer
• Dr. Ruud DobberExecutive Vice President - BioPharmaceuticals Business Unit
• Mr. David FredricksonExecutive Vice President - Oncology Business Unit
• Ms. Susan GalbraithExecutive Vice President - Oncology and Research and Development
• Ms. Iskra ReicExecutive Vice President, International
• Mr. Adrian KempCompany Secretary

Overall

91

Environment

88

Social

96

Governance

89

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.